Combination antimicrobial therapy for gram-negative infections: What is the evidence?

Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures

Volumn , Issue , 2007, Pages 433-459

  Safdar, Nasia ^a   Abad, Cybele L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953004128     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (177)

1. Maki DG. Risk factors for nosocomial infection in intensive care. Devices vs nature and goals for the next decade. Arch Intern Med 1989; 149:30-5.
2. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314.
3. Helfand MS, Bonomo RA. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol 2005; 5:452-8.
4. Kaye KS, Engemann JJ, Fraimow HS, et al. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2004; 18:467-511, viii.
5. Obritsch MD, Fish DN, MacLaren R, et al. Nosocomial infections due to multidrugresistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25:1353-64.
6. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med 2001; 29:N75-81.
7. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43-8.
8. Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005; 11:68-74.
9. Lautenbach E, Weiner MG, Nachamkin I, et al. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900.
10. Hsu DI, Okamoto MP, Murthy R, et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005; 55:535-41.
11. Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-32.
12. Kollef MH. Gram-negative bacterial resistance: evolving patterns and treatment paradigms. Clin Infect Dis 2005; 40(Suppl. 2):S85-8.
13. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-40.
14. Sanders CC, Sanders WE Jr. Clinical importance of inducible beta-lactamases in Gram-negative bacteria. Eur J Clin Microbiol 1987; 6:435-8.
15. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
16. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140:26-32.
17. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
18. Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-94.
19. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
20. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for Gramnegative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11:7-12.
21. Klibanov OM, Raasch RH, Rublein JC. Single versus combined antibiotic therapy for Gram-negative infections. Ann Pharmacother 2004; 38:332-7.
22. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-27.
23. Calandra T, Cometta A. Antibiotic therapy for Gram-negative bacteremia. Infect Dis Clin North Am 1991; 5:817-34.
24. Giamarellou H. Aminoglycosides plus beta-lactams against Gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986; 80:126-37.
25. Giamarellou H, Zissis NP, Tagari G, et al. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 25:534-6.
26. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in Gram-negative bacillary infections. Rev Infect Dis 1982; 4:294-301.
27. Moellering RC Jr, Eliopoulos GM, Allan JD. Beta-lactam/aminoglycoside combinations: interactions and their mechanisms. Am J Med 1986; 80:30-4.
28. Manian FA, Meyer L, Jenne J, et al. Loss of antimicrobial susceptibility in aerobic Gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol 1996; 17:222-6.
29. Weinstein RA. Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients. Chemioterapia 1985; 4:110-2.
30. Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501-9.
31. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-6.
32. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156:2121-6.
33. Osmon S, Ward S, Fraser VJ, et al. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125:607-16.
34. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110:847-55.
35. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344-55.
36. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44:87-93.
37. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
38. Binkley S, Fishman NO, LaRosa LA, et al. Comparison of unit-specific and hospitalwide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol 2006; 27:682-7.
39. Mena A, Plasencia V, Garcia L, et al. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol 2006; 44:2831-7.
40. Coelho J, Woodford N, Turton J, et al. Multiresistant Acinetobacter in the UK: how big a threat? J Hosp Infect 2004; 58:167-9.
41. Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42:5094-101.
42. Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48:4793-9.
43. Siebert JD, Thomson RB Jr, Tan JS, et al. Emergence of antimicrobial resistance in Gram-negative bacilli causing bacteremia during therapy. Am J Clin Pathol 1993; 100:47-51.
44. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006; 34:S20-8; discussion S64-73.
45. Kosmidis J, Koratzanis G. Emergence of resistant bacterial strains during treatment of infections in the respiratory tract. Scand J Infect Dis. (Suppl.) 1986; 49:135-9.
46. Barriere SL. Bacterial resistance to beta-lactams, and its prevention with combination antimicrobial therapy. Pharmacotherapy 1992; 12:397-402.
47. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27(Suppl. 2):S24-8.
48. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005; 40(Suppl. 2):S105-14.
49. Michea-Hamzehpour M, Auckenthaler R, Regamey P, et al. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31:1803-8.
50. Michea-Hamzehpour M, Pechere JC, Marchou B, et al. Combination therapy: a way to limit emergence of resistance? Am J Med 1986; 80:138-42.
51. Pechere JC. Emergence of resistance during beta-lactam therapy of Gram-negative infections. Bacterial mechanisms and medical responses. Drugs 1988; 35(Suppl. 2):22-8.
52. Pechere JC, Marchou B, Michea-Hamzehpour M, et al. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother 1986; 17(Suppl A):11-8.
53. Craig WA, Salamone FR. Do antibiotic combinations prevent the emergence of resistant organisms? Infect Control Hosp Epidemiol 1988; 9:417-9.
54. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.
55. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-58.
56. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997; 94:12106-11.
57. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-85.
58. Young LS. Review of clinical significance of synergy in Gram-negative infections at the University of California Los Angeles hospital. Infection 1978; 6(Suppl. 1):S47-52.
59. Gorschluter M, Hahn C, Fixson A, et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 2003; 11:362-70.
60. Bodey GP. Synergy. Should it determine antibiotic selection in neutropenic patients? Arch Intern Med 1985; 145:1964-6.
61. Sader HS, Jones RN. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents 2005; 25:380-4.
62. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(Suppl. 2):S95-9.
63. Tatman-Otkun M, Gurcan S, Ozer B, et al. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations. New Microbiol 2004; 27:21-8.
64. Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27:224-8.
65. Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006; 5:10.
66. Tascini C, Menichetti F, Gemignani G, et al. Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Int J Low Extreme Wounds 2006; 5:213-6.
67. Chang HY, Rodriguez V, Narboni G, et al. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976; 55:259-68.
68. Feld R, Bodey GP, Rodriguez V, et al. Causes of death in patients with malignant lymphoma. Am J Med Sci 1974; 268:97-106.
69. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490-4.
70. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
71. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a metaanalysis. Lancet Infect Dis 2002; 2:231-42.
72. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactamaminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326:1111.
73. Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003: CD003038.
74. Smith CE, Tillman BS, Howell AW, et al. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extendedspectrum beta-lactamase. Antimicrob Agents Chemother 1990; 34:1290-3.
75. Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47:841-53.
76. Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002; 137:77-87.
77. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
78. Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005; 33:2184-93.
79. Papazian L, Bregeon F, Thirion X, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996; 154:91-7.
80. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilatorassociated pneumonia in a large US database. Chest 2002; 122:2115-21.
81. Cunnion KM, Weber DJ, Broadhead WE, et al. Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Am J Respir Crit Care Med 1996; 153:158-62.
82. Craig CP, Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Infect Control 1984; 12:233-8.
83. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281-8.
84. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-9.
85. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-92.
86. Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988; 93:318-24.
87. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-94.
88. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-85.
89. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998; 157:371-6.
90. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
91. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29:2303-9.
92. Dupont H, Mentec H, Sollet JP, et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-62.
93. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
94. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35:228-35.
95. Dupont H, Montravers P, Gauzit R, et al. Outcome of postoperative pneumonia in the Eole study. Intensive Care Med 2003; 29:179-88.
96. Leroy O, Meybeck A, d’Escrivan T, et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003; 29:2170-3.
97. Mueller EW, Hanes SD, Croce MA, et al. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma 2005; 58:94-101.
98. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
99. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38:1309-13.
100. Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003; 2:75-107.
101. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.
102. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.
103. Sieger B, Berman SJ, Geckler RW, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25:1663-70.
104. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired Gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995; 20:1217-28.
105. Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17:497-504.
106. Paterson DL. Serious infections caused by enteric Gram-negative bacilli-mechanisms of antibiotic resistance and implications for therapy of Gram-negative sepsis in the transplanted patient. Semin Respir Infect 2002; 17:260-4.
107. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
108. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
109. Chow JW, Yu VL, Shlaes DM. Epidemiologic perspectives on Enterobacter for the infection control professional. Am J Infect Control 1994; 22:195-201.
110. Bouza E, Garcia de la Torre M, Erice A, et al. Enterobacter bacteremia. An analysis of 50 episodes. Arch Intern Med 1985; 145:1024-7.
111. Watanakunakorn C, Weber J. Enterobacter bacteremia: a review of 58 episodes. Scand J Infect Dis 1989; 21:1-8.
112. Burchard KW, Barrall DT, Reed M, et al. Enterobacter bacteremia in surgical patients. Surgery 1986; 100:857-62.
113. Gallagher PG. Enterobacter bacteremia in pediatric patients. Rev Infect Dis 1990; 12:808-12.
114. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004; 39:812-8.
115. Medeiros AA. Relapsing infection due to Enterobacter species: lessons of heterogeneity. Clin Infect Dis 1997; 25:341-2.
116. Cosgrove SE, Kaye KS, Eliopoulous GM, et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162:185-90.
117. Murray PR, Granich GG, Krogstad DJ, et al. In vivo selection of resistance to multiple cephalosporins by Enterobacter cloacae. J Infect Dis 1983; 147:590.
118. Black AS, Cohen J. Multiple beta-lactam resistance in Enterobacter cloacae following ceftazidime monotherapy. Lancet 1985; 2:331-2.
119. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23:454-61.
120. Kaye KS, Cosgrove S, Harris A, et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45:2628-30.
121. Gesser RM, McCarroll K, Teppler H, et al. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 2003; 51:1253-60.
122. Kim BN, Lee SO, Choi SH, et al. Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species. Int J Antimicrob Agents 2003; 22:106-11.
123. Stein GE. Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures. Pharmacotherapy 2005; 25:44S-54.
124. Anderson DJ, Engemann JJ, Harrell LJ, et al. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2006; 50:1715-20.
125. Hyle EP, Lipworth AD, Zaoutis TE, et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165:1375-80.
126. Tsay RW, Siu LK, Fung CP, et al. Characteristics of bacteremia between communityacquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162:1021-7.
127. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28:1718-23.
128. Lautenbach E, Metlay JP, Bilker WB, et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41:923-9.
129. Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50:1257-62.
130. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50:498-504.
131. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46:1481-91.
132. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115:942-9.
133. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-44.
134. Skippen I, Shemko M, Turton J, et al. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect 2006; 64:115-23.
135. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
136. Panhotra BR, Saxena AK, Al-Ghamdi AM. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. Saudi Med J 2004; 25:1871-6.
137. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992; 36:2639-44.
138. Garcia de la Torre M, Romero-Vivas J, Martinez-Beltran J, et al. Klebsiella bacteremia: an analysis of 100 episodes. Rev Infect Dis 1985; 7:143-50.
139. Feldman C, Smith C, Levy H, et al. Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect 1990; 20:21-31.
140. Baltch AL, Griffin PE. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients. Am J Med Sci 1977; 274:119-29.
141. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
142. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701-8.
143. Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52:668-74.
144. Mathews WC, Caperna J, Toerner JG, et al. Neutropenia is a risk factor for Gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: results of a nested case-control study. Am J Epidemiol 1998; 148: 1175-83.
145. Philippe E, Weiss M, Shultz JM, et al. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 1999; 7:83-7.
146. Vidal F, Mensa J, Martinez JA, et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 1999; 18:473-7.
147. Siegman-Igra Y, Ravona R, Primerman H, et al. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2:211-5.
148. Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. J Infect Dis 1974; 130(Suppl.):S14-23.
149. Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994; 18:886-95.
150. Chamot E, Boffi El Amari E, et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756-64.
151. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C beta-lactamase producing Gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997; 28:211-9.
152. Stone AM, Tucci VJ, Isenberg HD, et al. Wound infection: a prospective study of 7519 operations. Am Surg 1976; 42:849-52.
153. Lipsky BA, Hook EW III, Smith AA, et al. Citrobacter infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 1980; 2:746-60.
154. Bishara J, Gabay B, Samra Z, et al. Cellulitis caused by Citrobacter diversus in a patient with multiple myeloma. Cutis 1998; 61:158-9.
155. Shukla PC. Plantar cellulitis. Pediatr Emerg Care 1994; 10:23-5.
156. Hicks CB, Chulay JD. Bacteremic Citrobacter freundii cellulitis associated with tub immersion in a patient with the nephrotic syndrome. Mil Med 1988; 153:400-1.
157. Jones SR, Ragsdale AR, Kutscher E, et al. Clinical and bacteriologic observations on a recently recognized species of Enterobacteriaceae, Citrobacter diversus. J Infect Dis 1973; 128:563-5.
158. Chen YS, Wong WW, Fung CP, et al. Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia. J Microbiol Immunol Infect 2002; 35:109-14.
159. Samonis G, Anaissie E, Elting L, et al. Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 1991; 10:479-85.
160. Drelichman V, Band JD. Bacteremias due to Citrobacter diversus and Citrobacter freundii. Incidence, risk factors, and clinical outcome. Arch Intern Med 1985; 145:1808-10.
161. Hodges GR, Degener CE, Barnes WG. Clinical significance of Citrobacter isolates. Am J Clin Pathol 1978; 70:37-40.
162. Gupta N, Yadav A, Choudhary U, et al. Citrobacter bacteremia in a tertiary care hospital. Scand J Infect Dis 2003; 35:765-8.
163. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I betalactamase-producing organisms. Clin Infect Dis 1995; 21:1107-13.
164. Shih CC, Chen YC, Chang SC, et al. Bacteremia due to Citrobacter species: significance of primary intraabdominal infection. Clin Infect Dis 1996; 23:543-9.
165. Wang JT, Chang SC, Chen YC, et al. Comparison of antimicrobial susceptibility of Citrobacter freundii isolates in two different time periods. J Microbiol Immunol Infect 2000; 33:258-62.
166. Wisplinghoff H, Edmond MB, Pfaller MA, et al. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000; 31:690-7.
167. Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086-95.
168. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8:321-31.
169. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006: CD003344.
170. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005; CD002007.
171. Tascini C, Gemignani G, Ferranti S, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16:282-7.
172. Zuravleff JJ, Chervenick P, Yu VL, et al. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med 1984; 103:878-85.
173. Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J Lab Clin Med 1983; 101:896-902.
174. Gunderson BW, Ibrahim KH, Hovde LB, et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:905-9.
175. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998; 41:494-5.
176. Yoon J, Urban C, Terzian C, et al. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48:753-7.
177. Eggimann P, Revelly JP. Should antibiotic combinations be used to treat ventilatorassociated pneumonia? Semin Respir Crit Care Med 2006; 27:68-81.